Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 12 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 10 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

12(100.0%)

12Total

N/A(12)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials

NCT07452523Not ApplicableActive Not Recruiting

Tolerance, Palatability and Acceptability Evaluation of an Oral Nutrition Supplement

Role: lead

NCT07417514Not ApplicableRecruiting

Tolerance and Acceptability Evaluation of an Oral Nutrition Supplement

Role: lead

NCT04703894Not ApplicableCompleted

Tolerance and Acceptability Evaluation AYMES Cardiff

Role: lead

NCT04703881Not ApplicableCompleted

Tolerance and Acceptability Evaluation AYMES ActaGain

Role: lead

NCT04700293Not ApplicableCompleted

Tolerance and Acceptability Evaluation of AYMES AMSTERDAM

Role: lead

NCT03844373Not ApplicableCompleted

Tolerance and Acceptability Evaluation of STOCKHOLM

Role: lead

NCT02831647Not ApplicableCompleted

Acceptability and Tolerance Study of New Oral Nutritional Supplement PRAGUE

Role: lead

NCT03836274Not ApplicableCompleted

Tolerance and Acceptability Evaluation of MONACO

Role: lead

NCT03834896Not ApplicableCompleted

Madrid - Tolerance and Acceptability Study

Role: lead

NCT02898038Not ApplicableCompleted

Acceptability and Tolerance Study of a New Oral Nutritional Supplement (ONS)

Role: lead

NCT02648451Not ApplicableCompleted

Acceptability and Tolerance Study of New Oral Nutritional Supplement

Role: lead

NCT02639156Not ApplicableCompleted

Acceptability and Tolerance of New Oral Nutritional Supplement

Role: lead

All 12 trials loaded